Neuroone medical technologies corporationNMTC.US Overview

NMTC Earnings Table

• When is NMTC's latest earnings report released?

  The most recent financial report for Neuroone medical technologies corporation (NMTC) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NMTC's short-term business performance and financial health. For the latest updates on NMTC's earnings releases, visit this page regularly.

• What is the operating profit of NMTC?

  According to the latest financial report, Neuroone medical technologies corporation (NMTC) reported an Operating Profit of -1.71M with an Operating Margin of -59.02% this period, representing a decline of 199.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

• How is NMTC's revenue growth?

  In the latest financial report, Neuroone medical technologies corporation (NMTC) announced revenue of 2.89M, with a Year-Over-Year growth rate of -53.9%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

• How much cash does NMTC have?

  At the end of the period, Neuroone medical technologies corporation (NMTC) held Total Cash and Cash Equivalents of 3.56M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

• Does NMTC go with three margins increasing?

  In the latest report, Neuroone medical technologies corporation (NMTC) did not achieve the “three margins increasing” benchmark, with a gross margin of 54.2%%, operating margin of -59.02%%, and net margin of -49.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NMTC's profit trajectory and future growth potential.

• Is NMTC's EPS continuing to grow?

  According to the past four quarterly reports, Neuroone medical technologies corporation (NMTC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

• What is the FCF of NMTC?

  Neuroone medical technologies corporation (NMTC)'s Free Cash Flow (FCF) for the period is -3.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,818.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.